纽约 - 根据InvestingPro数据显示，过去一周股价上涨近10%的Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)报告了一项临床试验的积极结果。该试验研究了Actimab-A与CLAG-M化疗联合用于复发或难治性急性髓系白血病 (r/r ...

Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ...

Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...

Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...

In a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According to ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...